Skip to main content

Advertisement

Fig. 2 | Genome Medicine

Fig. 2

From: The neoepitope landscape in pediatric cancers

Fig. 2

The landscape of neoepitopes in 540 pediatric cancer patients of 23 subtypes. The number of predicted epitopes and expressed epitopes is shown for each sample. The results are shown by the three major cancer types (i.e., leukemia, CNS tumors, and solid tumors) with each of the 23 cancer subtypes shown in a box. Within each cancer subtype, the tumor samples are sorted by ascending order of the number of predicted epitopes. The numbers of total epitopes and expressed epitopes are depicted at the top and the bottom mirrored panels, respectively. The relapse samples are shown as cross marks in grey. The samples without RNAseq are shown in blue. The upper bound is set to 30 and the values > 30 are shown in red. Leukemia: ETV ETV6-RUNX1 acute lymphoblastic leukemia (ALL); BALL B-lineage ALL; HYPER hyperdiploid ALL; HYPO hypodiploid ALL; TALL T-lineage ALL; ERG ALL with alterations of ERG; INF infant ALL; CBF core binding factor leukemia; PHALL Ph + (Philadelphia) ALL; E2A B-lineage ALL; E2A E2A-PBX1 dsubtype; A M7 subtype of AML (acute megakaryoblastic leukemia). CNS tumors: HGG high-grade glioma; EPD ependymoma; MB medulloblastoma; LGG low-grade glioma; C choroid plexus carcinoma. SOLID tumors: M melanoma; OS osteosarcoma; NBL neuroblastoma; RHB rhabdomyosarcoma; ACT adrenocortical tumor; RB retinoblastoma; EWS Ewing’s sarcoma

Back to article page